Infectious Complications of Biologic Agents

Rheumatic Disease Clinics of North America

Volumn 35, Issue 1, 2009, Pages 183-199

  Martin Mola, Emilio ^a   Balsa, Alejandro ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Abatacept; Biologic agents; Infections; Rheumatoid arthritis; Rituximab; TNF antagonists; Tocilizumab; Tuberculosis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFECTIVE AGENT; ATLIZUMAB; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; ISONIAZID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

BACTERIAL PNEUMONIA; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CYSTITIS; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HAZARD RATIO; HERPES ZOSTER; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; INFECTION COMPLICATION; INFECTION RISK; LEGIONNAIRE DISEASE; LEISHMANIASIS; LISTERIOSIS; LOW DRUG DOSE; META ANALYSIS; MYCOBACTERIOSIS; NONTUBERCULOUS MYCOBACTERIAL INFECTION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RARE DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SPAIN; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXOPLASMOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65749083869     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2009.03.009     Document Type: Review

References (75)

1. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46 (2002) 2287-2293
2. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35 (2008) 387-393
3. Carmona L., Hernandez-Garcia C., Vadillo C., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30 (2003) 1436-1439
4. Wolfe F., Caplan L., and Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54 (2006) 628-634
5. Schneeweiss S., Setoguchi S., Weinblatt M.E., et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 56 (2007) 1754-1764
6. Furst D.E., Schiff M.H., Fleischmann R.M., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30 (2003) 2563-2571
7. Klareskog L., van der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
8. Genovese M.C., Bathon J.M., Fleischmann R.M., et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 32 (2005) 1232-1242
9. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
10. St. Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
11. Weinblatt M., Schiff M., Goldman A., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 66 (2007) 228-234
12. Weinblatt M., Combe B., Covucci A., et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816
13. Klareskog L., Gaubitz M., Rodriguez-Valverde V., et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 65 (2006) 1578-1584
14. Davis Jr. J.C., van der Heijde D.M., Braun J., et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67 (2008) 346-352
15. Lovell D.J., Reiff A., Ilowite N.T., et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58 (2008) 1496-1504
16. Weisman M.H., Paulus H.E., Burch F.X., et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) 46 (2007) 1122-1125
17. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
18. Leombruno J.P., Einarson T.R., and Keystone E.C. The safety of anti-Tumor Necrosis Factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis (2008) [epub ahead of print]
19. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
20. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
21. Askling J., Fored C.M., Brandt L., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66 (2007) 1339-1344
22. Dixon W.G., Symmons D.P., Lunt M., et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56 (2007) 2896-2904
23. Patkar N.M., Teng G.G., Curtis J.R., et al. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 20 (2008) 320-326
24. Takeuchi T., Tatsuki Y., Nogami Y., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67 (2008) 189-194
25. Abe T., Takeuchi T., Miyasaka N., et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 33 (2006) 37-44
26. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
27. Salliot C., Gossec L., Ruyssen-Witrand A., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 46 (2007) 327-334
28. Curtis J.R., Patkar N., Xie A., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56 (2007) 1125-1133
29. Curtis J.R., Xi J., Patkar N., et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56 (2007) 4226-4227
30. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clin Infect Dis 41 Suppl 3 (2005) S199-S203
31. den Broeder A.A., Creemers M.C., Fransen J., et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34 (2007) 689-695
32. Ruyssen-Witrand A., Gossec L., Salliot C., et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 25 (2007) 430-436
33. Dixon W.G., Lunt M., Watson K., et al. Anti-TNF therapy and the risk of serious post-operative infection: results from the BSR biologics register (BSRBR). [abstract]. Ann Rheum Dis 66 Suppl II (2007) 118
34. Askling J., and Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 20 (2008) 138-144
35. Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions. J Rheumatol 34 (2007) 653-655
36. Nishimoto N., Miyasaka N., Yamamoto K., et al. Safety profile of tocilizumab in Japanese patients with rheumatoid arthritis. Incidences of infections in Japanese long-term clinical studies. [abstract]. Ann Rheum Dis 67 Suppl II (2008) 335
37. Hoshi D., Nishimoto N., Inoue E., et al. Incidence of infections in Japanese rheumatoid arthritis patients treated with tocilizumab (TCZ) in clinical studies in comparison to those in an observational cohort of Japanese patients, IORRA. Ann Rheum Dis 67 Suppl II (2008) 200
38. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
39. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
40. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
41. Keystone E., Fleischmann R., Emery P., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56 (2007) 3896-3908
42. Strangfeld A., Hierse F., Listing J., et al. RA patients treated with Rituximab. Routine care data of the German Biologics Register RABBIT. [abstract]. Arthritis Rheum 58 Suppl (2008) S305
43. Genovese M.C., Breedveld F.C., Emery P., et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis (2009) [epub ahead of print]
44. Hochberg M.C., and Simon T.A. Safety of abatacept in patients with rheumatoid arthritis. [abstract]. Ann Rheum Dis 67 Suppl II (2008) 36
45. Smitten A.L., Simon T.A., Qi K., et al. Hospitalized infections in the abatacept RA clinical development program: an epidemiological assessment with >10,000 person-years of exposure. [abstract]. Arthritis Rheum 58 Suppl (2008) S786-S787
46. Salliot C., Dougados M., and Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68 (2009) 25-32
47. Lassoued S., Zabraniecki L., Marin F., et al. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum 36 (2007) 262-263
48. Gluck T., Linde H.J., Scholmerich J., et al. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 46 (2002) 2255-2257
49. Aparicio A.G., Munoz-Fernandez S., Bonilla G., et al. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthritis Rheum 48 (2003) 1764-1765
50. Jain V.V., Evans T., and Peterson M.W. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med 100 (2006) 1291-1293
51. Tektonidou M.G., and Skopouli F.N. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?. Clin Rheumatol 27 (2008) 541-542
52. Bergstrom L., Yocum D.E., Ampel N.M., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50 (2004) 1959-1966
53. Li G.F., Benucci M., and Del R.A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab). J Clin Rheumatol 11 (2005) 119-120
54. Tubach F., Ravaud P., Salmon-Ceron D., et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 43 (2006) e95-e100
55. FDA. Available at:. www.fda.gov/cder/foi/label/2006/103705s5230-s5231lbl.pdf Accessed Feb 2009
56. FDA. Available at:. www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf Accessed Feb 2009
57. WHO. Tuberculosis. Available at:. http://www.who.int/tb/en/ Accessed Feb 2009
58. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005) 1986-1992
59. Seong S.S., Choi C.B., Woo J.H., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34 (2007) 706-711
60. Wolfe F., Michaud K., Anderson J., et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50 (2004) 372-379
61. Brassard P., Kezouh A., and Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43 (2006) 717-722
62. Winthrop K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2 (2006) 602-610
63. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
64. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127
65. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
66. Wallis R.S., Broder M., Wong J., et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39 (2004) 1254-1255
67. Gomez-Reino J.J., Carmona L., and Angel D.M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57 (2007) 756-761
68. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52 (2005) 1766-1772
69. Sichletidis L., Settas L., Spyratos D., et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10 (2006) 1127-1132
70. Sibilia J., and Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 25 (2007) S46-S56
71. Genovese M.C., McKay J.D., Nasonov E.L., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58 (2008) 2968-2980
72. Emery P., Keystone E., Tony H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008) 1516-1523
73. Smolen J.S., Keystone E.C., Emery P., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 143-150
74. von Reyn C.F., et al. Nontuberculous mycobacteria. In: Fauci A.S., and Braunwald E. (Eds). Harrison's principles of internal medicine. 17th edition (2008), McGraw-Hill Companies, Inc., New York 1027-1032
75. Winthrop K.L., Yamashita S., Beekmann S.E., et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 46 (2008) 1738-1740